that TNF stimulates release from EC of PDGF-like molecules (PDGF,) . This effect may be partially mediated by EC release of autocrine IL-1, or may involve other mediators .
Materials and Methods
Endothelial Cell Culture. Human umbilical vein EC were cultured according to published methods (21) (22) (23) (24) . Briefly, early passage (P2-P 5) EC were grown to confluency on gelatin-coated 24-well tissue culture plates (Falcon Labware, Oxnard, CA) . The cells were plated at a density of 4 x 104 cells per well, reached confluence by 48-72 h, and were used within 3-5 d of plating. Culture medium consisted of Medium 199 (Grand Island Biological Co., Grand Island, NY) containing 50 U/ml penicillin, 50 P.g/ml streptomycin, 2.5 tag/ml fungizone, 2.0 mM t.-glutamine, 20 wg/ml endothelial cell growth factor (Meloy Laboratories, Inc., Springfield, VA), 90 gg/ml porcine intestinal mucosa heparin (170 USP units/mg), and 20% pooled human serum. For cell passage, monolayers were washed with Hepes-buffered saline, and incubated for 5 min in the same containing 0.05% Type I collagenase, 0.01% EDTA, and 0 .25% BSA at 37°C. After addition of an equal volume of serum-containing medium, the cells were washed once, resuspended, and plated . Cells were grown at 37°C in a humidified atmosphere with flowing 5% C02/95% air .
SMC Culture. SMC were cultured from bovine arteries by the procedures of Ross (25) and Hajjar et al. (26) . Briefly, early passage (P2-P6) SMC were grown from explants on Falconware in MEM (Gibco Laboratories, Grand Island, NY) containing 50 U/ml penicillin, 50 ug/ml gentamicin, 2.5 lAg/ml fungizone, 2.0 MM L-glutamine, and 20% FCS (heatinactivated) . For routine cell passage, cultures were washed, removed from the plates, and replated (25, 26) . Cells were propagated in a humidified atmosphere containing 5% C02/95% air at 37°C .
Treatment of Endothelial Cells with TNF and IL-1 . Confluent EC were washed twice with PC-1 medium (Ventrex Laboratories Inc ., Portland, ME), and treated for various periods of time (2-24 h) with PC-1 containing various concentrations (0-3.0 nM) of recombinant human TNF (Genentech, South San Francisco, CA) or recombinant IL-10 . IL-1/3 was a gift from Dr. Charles Dinarello, Tufts University School of Medicine, Boston, MA. The resulting postculture medium was harvested and added immediately to semiconfluent bovine SMC previously washed twice with PBS . In some experiments, polymyxin B (10,ug/ml ; Sigma Chemical Co., St. Louis, MO) was added to exclude possible endotoxin effects (27) .
Treatment of Endothelial Cells with Actinomycin D. Cells were preincubated with 0.16 tM actinomycin D (Sigma Chemical Co.) for 30 or 120 min (28) , and then washed three times with PC-1 before treatment with TNF as described above.
Mitogenesis Assay. Mitogenic activity of arterial SMC was measured as described extensively by DiCorleto and Bowen-Pope (29) . All samples were assayed in quadruplicate ; standard deviations averaged 10% of the mean.
Lactate Dehydrogenase (LDH)-release Assay. LDH activity in postculture medium was measured using a commercially available kit (Sigma LD-L; Sigma Chemical Co.), according to the method of Wacker et al. (30) . Release of LDH from EC was determined for postculture medium samples after treatment of cells with PC-1 alone, PC-1 plus TNF, or sonication at 4°C (Heat Systems-Ultrasonics, Inc ., Farmingdale, NY; power 4, duty cycle 40%, 10-s continuous pulse) . Linearity of the assay was verified using normal and high LDH standards provided by the manufacturer.
Immunoinhibition Studies. Postculture medium from TNF-stimulated cells was preincubated with rabbit anti-human platelet PDGF. This antibody, a gift from Dr. Thomas Deuel, Washington University, St. Louis, MO, was obtained from rabbits immunized with purified human PDGF and judged monospecific in immunodiffusion analyses against platelet lysates, serum, and plasma (31) . Additional samples of postculture medium were preincubated with anti-EC antibody (24) , or nonimmune goat serum (CooperBiomedical, Inc., Malvern, PA) as described in the figure legends . In some experiments, EC were stimulated with TNF in the presence of various antibodies, including rabbit anti-recom- Northern Blot Analysis. Human umbilical vein EC (P,) were grown to confluency in 75-cm' flasks (Falcon Labware) . The cells were washed twice with PC-1, and then treated with either TNF (25 ng/ml in PC-1) or PC-1 alone and incubated for 18 h at 37°C in a 5% C02 humidified incubator. The cell monolayers were then washed three times with Hepes-buffered saline and detached with 0 .05% Type I collagenase, 0 .01% EDTA, and 0 .25% BSA (5 min, 37°C). Cells in the resulting single-cell suspension (total number of EC^-22 .5 X 10 6, treated and control) were washed three times with PBS . Total cellular RNA was prepared from these pellets by extraction in 4 M guanidium isothiocyanate, 5 mM sodium citrate, 0 .1 M 2-ME, and 0 .5% sarkosyl followed by centrifugation through CsCI (32, 33) . Total cellular RNA (14 wg) from TNF-treated or control cells was first denatured with formaldehyde, electrophoresed in a 1 % agarose gel, and then transferred to nitrocellulose filters (33) . In addition, 30 Ag of total cellular RNA isolated from the human melanoma cell line A875 was electrophoresed and transferred . Hybridization was carried out at 42'C for 15 h in 50% formamide, I X Denhart's solution, 100 tag/ml salmon sperm DNA, 10% Dextran sulfate, 0 .75 M NaCl, 0 .075 M sodium citrate, 0 .05 M NaH 2 PO4 H 2 O, 5 mM EDTA, pH 7 .4, using a '2 P-labeled c-sis DNA probe nick-translated to a sp act of 3 .9 X 10 7 dpm/Pg . The c-sis probe used was a 1 .6-kb Barn HI human genomic fragment designated PI 335 and was generously provided by F . Wong-Staal and R . Gallo, National Institutes of Health, Bethesda, MD (34) . The filter was then washed in 0 .3 M NaCl, 0 .03 M sodium citrate, 0 .1% SDS, pH 7 .0, at 68°C and autoradiograms were obtained after 5, 14, and 24 h of exposure . The relative intensity of the sis probe hybridizing band was estimated by laser densitometric scanning of the autoradiograms .
Results
Incubation of SMC with postculture medium from EC stimulated with various doses of TNF for 18 h led to a dose-dependent and saturable increase in incorporation of [ 'H]thymidine into SMC (Fig . I A) . This stimulatory effect became maximal at a TNF dose of^-10 ng/ml (570 pM) where the rate of SMC proliferation was increased 90% over controls . Half-maximal stimulation was reached at a TNF dose of -2 ng/ml, resulting in an EC 50 for this interaction of 114 pM. This increase in [sH]thymidine incorporation was paralleled by cellular proliferation as cell counts rose from a mean of 52,000 ± 4,004 (SE, n = 4) to a mean of 147,500 ± 14,362 (SE, n = 4) after 18 h of treatment with TNF (10 ng/ml). A similar effect was achieved by stimulating EC with IL-1 (60-250 pM), which resulted in a 100% increase in the SMC proliferation rate (Fig. 1 B) . These results suggest a high affinity interaction between these monokines and the endothelial cell involving one or more specific binding sites.
The time course for the production of mitogenic activity by TNF stimulation of EC is shown in Fig . 2 . A slight (34 .7-43 .5%) increase in mitogenic activity was detectable after 2-6 h of TNF stimulation . This was followed by a major peak of activity at 15 h, which represented a tripling of baseline activity and persisted for up to 24 h . Thus, the initial small increase in mitogenic activity might reflect constitutive release of PDGFc while it appears that an initial lag period may be required for full expression of the stimulatory effect of TNF .
To determine whether the mitogenic effect of EC postculture medium could be attributed to passive transfer of TNF, the direct effect of TNF on SMC mitogenesis was studied . Only a slight increase in mitogenesis (17%) was observed at concentrations of 53.2 ng/ml (3.0 nM) . This dose was^-10 times that used routinely to stimulate EC that responded with a 100-300% increase in SMC proliferation . Postculture medium from nonstimulated EC showed minimal enhancement of [sH]thymidine incorporation into dividing SMC (32 ± 6%, SE), even when added to SMC in the presence of TNF (10 ng/ml) (34 .4 ± 4%, SE). IL-1 alone had no mitogenic effect when added directly to SMC . In addition, polymyxin B had no effect on SMC mitogenesis in response to postculture medium from TNF-stimulated EC .
Immunoinhibition studies were carried out to examine the mechanism by which postculture medium from TNF-stimulated EC promoted SMC proliferation (Fig. 3) . Postculture medium from nonstimulated EC enhanced SMC mitogenesis by 29 .4%, while postculture medium from TNF-stimulated cells produced a 96.8% increase in mitogenic activity. When TNF-stimulated postculture medium was preincubated with anti-platelet PDGF, its mitogenic activity was completely abrogated (0%) and cellular proliferation returned to the baseline level. Antibody to intact EC and nonimmune goat serum failed to significantly inhibit mitogenic activity (94 .9 and 123.3% of control, respectively) produced by TNF stimulation. In similar experiments, mitogenic activity in postculture medium from nontreated EC was partially (68.8%) inhibited by treatment with anti-PDGF at a dilution of 1 :200 (49,108 ± 17,518 cpm/well ± SE, n = 4) as compared with treatment without antibody (157,465 ± 11,919 cpm/well ± SE, n = 4) or with control (anti-EC) antibody (103,530 ± 23,660 cpm/well ± SE, n = 4). Anti-PDGF also blocked the mitogenic activity induced by IL-1-stimulated EC (data not shown) . Thus, PDGF-like molecules appeared to play a major role in stimulating SMC proliferation .
Treatment of EC with TNF in the presence of anti-IL-1 enhanced SMC mitogenic activity to 58 .9% (± 2 .2%, SE, n = 4) over control as compared with a 97.4% (± 4.1 %, SE, n = 4) increase over control for TNF alone (Fig. 4) . When EC were treated with TNF in the presence of an irrelevant antibody (anti-EC), the SMC proliferative effect in the resulting postculture medium represented an 80.9% (± 7 .6%, SE, n = 3) increase over control . These results suggested that elaboration of SMC proliferative activity by TNF-stimulated EC may have been partially mediated by TNF-induced secretion of autocrine IL-I by the endothelial cell .
The effect of inhibition of RNA synthesis on production of mitogenic activity by TNF-stimulated EC was also examined. Preincubation of EC with 0.16 JIM actinomycin D for 120 min blocked all but 26.3% of mitogenic activity released by TNF-treated EC, while after 30 min of actinomycin D blockade, release of Effect of Actinomycin D on TNF-induced PDGF, Release by EC EC were prepared as described in the legend to Fig. 1 . After two washes with PC-1, EC monolayers were preincubated with actinomycin D (0 .16 UM in PC-1) for 30 min or 120 min as indicated. Culture medium was then removed, and the cells were washed twice with PC-1, and incubated with TNF (0 .08 nM) in PC-1 or PC-I alone for 18 h. The resulting EC postculture medium (ECCM) was then added to proliferating SMC and its mitogenic activity was assessed . Activity is expressed as [SHjthymidine incorporation (dpm ± SE, n = 4), and as percent above control (ECCM). mitogenic activity by TNF was 68.0% of control (Table I ). This inhibitory effect did not reflect cell death or injury since neither exclusion of trypan blue nor release of LDH in actinomycin D-treated samples was elevated over untreated controls (data not shown) . In addition, Northern blot analysis was carried out. Both TNF and control EC showed a strong band at^-3.5-3.7 kb hybridizing with the specific sis probe (Fig. 5) . Melanoma cells did not express the sis gene. Densitometric analysis revealed a 2.5-fold increased expression of the sis gene by the TNF-treated cells compared with control . In addition, a minor band at -4.3 kb was also noted in the TNF-treated samples ; the significance of this band is currently unknown.
Discussion
The present data indicate for the first time that recombinant human TNF stimulates release of an EC factor that is mitogenic for bovine SMCs and that is completely neutralized by antibody to platelet PDGF. Elaboration of PDGFc appears to be dose related and saturable, with half-maximal stimulation occurring at^-2 ng/ml (-114 pM) TNF, suggesting the presence of discrete, high-affinity binding sites (Fig. 1 A) for this peptide. In agreement with the literature (12), a similar effect was achieved by stimulation with rIL-1 at 1-4 ng/ml (60-240 pM) (Fig. 1 B) .
The mitogenic activity in postculture medium from TNF-stimulated EC can be completely neutralized by antibody to platelet PDGF (Fig. 3) . Thus, PDGF are apparently released by EC in response to TNF challenge . Although freshly isolated adult rat SMC produce PDGF during their first few days in culture (35, 36) , the rate of production of PDGF declines upon further subculture, suggesting that the mitogenic effect in these passaged cells is not due to autocrine stimulation by endogenous PDGF from SMC. TNF alone at doses up to 53 ng/ml had no significant mitogenic effect on bovine SMC . Therefore, the observed proliferation cannot be attributed to passive transfer of TNF in the postculture medium.
Time-course studies (Fig. 2) suggested that the major release of mitogenic activity occurs only after 6 h of TNF stimulation . Earlier time points showed only a slight (35-45%) increase in activity, which probably reflects constitutive production of PDGF (16, 29) . This finding raises the question of whether a series of intermediate events might be required before release of PDGF in response to TNF occurs. Upon stimulation with thrombin (20) , human EC released PDGF in an approximately linear fashion for up to 24 h; significant PDGF release was first detected at 1 .5 h . Bovine EC elaborate PDGF after challenge with factor Xa in an apparently biphasic fashion over 16 h, with first appearance of PDGF within as early as 2 min (19) . These various release patterns may reflect differential modes of agonist processing by the endothelial cell, and suggest that these agents may act through different mechanisms.
Release of PDGF from human umbilical vein EC was associated with PDGFspecific RNA synthesis since c-sis hybridizable RNA was increased 2.5-fold after TNF stimulation of EC (Fig. 5) , and since release of proliferative activity was substantially inhibited by preincubating cells with actinomycin D (Table I) . In cultured adipocytes, TNF is known to downmodulate the activity of differentiation-specific enzymes such as lipoprotein lipase by acting at the level of transcription (37) (38) (39) (40) . Similarly, in dermal fibroblasts and synovial cells, TNF enhances production of prostaglandin E2 and collagenase (41) . In addition, the recently reported effects of TNF on the endothelial cell, such as induction of IL-1 secretion (9, 10) , increase in tissue factor activity (6, 7) , and promotion of neutrophil adhesion (42) also appear to reflect new synthesis of mRNA and hence protein . It now appears that the observed release of PDGF from EC may represent an additional example of gene expression that is controlled by this inflammatory mediator .
TNF is known to bind to human umbilical vein EC (apparent Kd -125 pM) and to augment release of IL-1 through a protein synthesis-dependent mechanism (9, 10) . Immunoinhibition studies reported herein (Fig. 4) indicate that TNF-induced release of PDGF, by EC was partially blunted by antibody to IL-1, suggesting a role for this monokine. On the other hand, the release of mitogenic activity was also clearly associated with a several-fold increase in synthesis of mRNA specific for PDGF,. Therefore, it appears that PDGF, release may reflect a dual mechanism, involving both secretion of autocrine IL-1 and de novo synthesis of PDGF,.
In the endothelial cell, TNF is an important inducer of IL-1 secretion (9, 10). IL-1, in turn, appears to feed back upon the cell, thereby modulating its role in hemostasis by promoting its procoagulant properties (43, 44) , and by inducing synthesis of plasminogen activator-inhibitor (45) (46) (47) . In addition, both monokines promote leukocyte adhesion to endothelial monolayers (42, 48) . Our data suggest an additional role for TNF, namely release of EC-derived PDGF,. Thus, through a series of cell-cell interactions, the release of key monokines may play an important role in vessel wall biology, not only by favoring the maintenance of fibrin, but also by modulating vascular tone (49) and SMC proliferation. In this way, TNF and IL-1 may play a role in both normal and abnormal responses to vascular inflammation, wound healing, and atherogenesis. Summary Platelet-derived growth factor (PDGF) is a 30,000-Mr glycoprotein that is chemotactic and mitogenic for vascular smooth muscle cells (SMC). It is also a potent vasoconstrictor . In the present study, we found that the macrophagederived polypeptide, tumor necrosis factor (TNF), releases a factor from human umbilical vein endothelial cells (EC) that is mitogenic for SMC. Postculture medium from TNF-stimulated EC induced a 90% increase in mitogenesis as compared with controls . This effect was half-maximal at a TNF dose of 114 pM, reflected a 2.5-fold increase in PDGF-specific mRNA synthesis, and peaked at 15 h of TNF stimulation. Mitogenic activity was completely abrogated by preincubation of postculture medium with antibody to platelet PDGF. Stimulation of EC with IL-1 (60-240 pM) led to the release of similar mitogenic activity . Thus, in addition to its effects on the hemostatic and adhesive properties of EC, TNF also promotes release of PDGF, which may serve to modulate proliferation of vascular SMC during wound healing, inflammation, and atherogenesis.
